Product Description
Dexmedetomidine is a new generation highly selective a2-adrenergic receptor (a2-AR) agonist that is associated with sedative and analgesic sparing effects, reduced delirium and agitation, perioperative sympatholysis, cardiovascular stabilizing effects, and preservation of respiratory function.
Mechanisms of Action: ADRA2A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Nasal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Bipolar Disorder | Schizophrenia
Known Adverse Events: Hypotension | Hypotension, Orthostatic | Dizziness | Paresthesia
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Egypt, United States
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|Anesthesia Related|COVID-19|Other
Phase 2: Pain, Postoperative
Phase 1: Acute Pain|Alcoholism|Chronic Pain|Depressive Disorder|Healthy Volunteers|Neuropathic Pain|Nociceptive Pain|Stress Disorders, Post-Traumatic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AS210006-A08 | P1 |
Not yet recruiting |
Stress Disorders, Post-Traumatic|Alcoholism |
2025-09-30 |
|
| Alaa Abdel-Khalek | P1 |
Not yet recruiting |
Neuropathic Pain|Pain, Postoperative|Depressive Disorder|Acute Pain|Chronic Pain|Nociceptive Pain |
2024-11-01 |
43% |
| Alaa Abdel-Khalek | P1 |
Not yet recruiting |
Neuropathic Pain|Pain, Postoperative|Depressive Disorder|Acute Pain|Chronic Pain|Nociceptive Pain |
2024-11-01 |
43% |
| AS170014-A7 | P1 |
Completed |
Stress Disorders, Post-Traumatic|Alcoholism |
2023-05-02 |
|
| PET-DEXDO COVID | P3 |
Active, not recruiting |
Acute Respiratory Distress Syndrome|COVID-19 |
2022-06-11 |